Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 26;14(4):e24515.
doi: 10.7759/cureus.24515. eCollection 2022 Apr.

Desensitization Protocol to Carboplatin: A Technical Report

Cornelia Nitipir  1   2 , Andreea Parosanu  1   2 , Ana Maria Popa  2   1 , Horia Cotan  1 , Mihaela Olaru  1   2 , Cristian Iaciu  1   2 , Cristina Orlov Slavu  1   2
Affiliations

Desensitization Protocol to Carboplatin: A Technical Report

Cornelia Nitipir et al. Cureus. .

Abstract

Carboplatin is one of the most widely used chemotherapy agents for solid tumors. One of the most common major side effects is the hypersensitivity reaction, and the likelihood of it increases with the number of courses given. Permanent discontinuation of carboplatin is not required if this side effect occurs. Using an effective desensitization protocol, this type of event can be avoided so that the patient continues to benefit from the maximum antitumor effect. This technical report is meant to detail the desensitization protocol designed and followed in the Oncology Clinic of the University Emergency Hospital, Bucharest.

Keywords: carboplatin; desensitization; hypersensitivity; protocol; reaction.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Broome CB, Schiff RI, Friedman HS. Med Pediatr Oncol. 1996;26:105–110. - PubMed
    1. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. J Allergy Clin Immunol Pract. 2016;4:497–504. - PubMed
    1. Platinum hypersensitivity and desensitization. Miyamoto S, Okada R, Ando K. Jpn J Clin Oncol. 2015;45:795–804. - PubMed
    1. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. Castells MC, Tennant NM, Sloane DE, et al. J Allergy Clin Immunol. 2008;122:574–580. - PubMed
    1. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Castells M. Front Immunol. 2017;8:1472. - PMC - PubMed

LinkOut - more resources